TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Intraocular Pressure During Abdominal Aortic Aneurysm (AAA) Repair

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients presenting to St. Boniface General Hospital for elective AAA repair requiring an arterial line, central line and general anesthesia will be eligible for inclusion in this study.~Exclusion Criteria:~* . The exclusion criteria for this study are:~  1. Patients with a history of acute or chronic eye disease~ 2. Allergy to topical ophthalmologic anesthesia~ 3. Patients receiving nitrous oxide, ketamine or succinylcholine during anesthesia~ 4. If the surgical procedure will require the aorta to be re-clamped following unclamping, those patients will also be excluded~ 5. Patients that are VRE+ or MRSA+ will be excluded for infection control purposes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Postoperative Intermittent Intrauterine Balloon Dilatation Therapy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. women aged 18-40 years;~2. moderate to severe intrauterine adhesion (AFS score≥5);~3. no previous history of hysteroscopic adhesiolysis in our hospital;~4. written consent obtained~5. agreement to have second-look and third-look hysteroscopy.~Exclusion Criteria:~1. minimal adhesion (AFS score \<5);~2. previous hysteroscopic adhesiolysis in our hospital.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- IUB dilatation therapy (Type: EXPERIMENTAL): The patient will have Foley-catheter intrauterine balloon dilatation 2 weeks and 6 weeks after hysteroscopic adhesiolysis. A second-look hysteroscopy will be carried out in the early proliferative phase 4 weeks after the surgery and third-look hysteroscopy will be carried out 8 weeks after the surgery.
- control group (Type: NO_INTERVENTION): Patient will not undergo any balloon therapy. A second-look hysteroscopy will be carried out in the early proliferative phase 4 weeks after the surgery and third-look hysteroscopy will be carried out 8 weeks after the surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Inotropic Potential of Apelin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Healthy volunteers:~\>18yrs~Heart failure patients;~* New York Heart Failure class II-IV~* Ejection fractional \<35% or fractional shortening \<20% within previous 6months.~Exclusion Criteria:~All subjects,~* Females of child bearing age not on adequate contraception~* Lack of informed consent~* Age \<18yrs~* Current involvement in any other research study~* Systolic BP \>190 or \<100~* Malignant arrhythmias~* Renal or hepatic failure~* Haemodynamically significant aortic stenosis~* Severe or significant co-morbidity~* Pacemakers~Healthy volunteers~* Any regular medication~* Previous history of any cardiovascular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Apelin infusion (Type: EXPERIMENTAL): 6 hour infusion of apelin peptide into circulation
- Placebo (Type: PLACEBO_COMPARATOR): Infusion of saline into systemic circulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Have a body mass index (BMI) within the range of 18.0 to 30.0 kg/m2, inclusive, and a minimum weight of at least 50.0 kg~* Be a current recreational opioid user who has used opioids for non-therapeutic purposes (ie for psychoactive effects) at least 10 times in their lifetime~* Agree to use an approved method of contraception for the duration of the study unless surgically sterile or postmenopausal~* Be willing and able to abide by all study requirements and restrictions~* Additional criteria may apply~Exclusion Criteria:~* Have evidence of drug or alcohol dependence within the past 2 years~* Have a positive drug screen for opioids, amphetamines, cocaine, or benzodiazepines upon admission to the clinic~* Have a history of severe allergic reaction (including anaphylaxis) to any food, medication, or bee sting~* Be currently pregnant, breastfeeding, or planning to become pregnant during the study~* Currently have or have a history of allergy or hypersensitivity to opioid agonists, opioid antagonists or related drugs (eg, oxycodone, morphine, naltrexone, and naloxone)~* Have a positive test result for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)~* Have donated or lost more than 500 mL whole blood~* Additional criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- ALKS 5461 Dose 1 (Type: EXPERIMENTAL): Sublingual tablets
- ALKS 5461 Dose 2 (Type: EXPERIMENTAL): Sublingual tablets
- ALKS 5461 Dose 3 (Type: EXPERIMENTAL): Sublingual tablets
- Buprenorphine Dose 1 (Type: ACTIVE_COMPARATOR): Sublingual tablets
- Buprenorphine Dose 2 (Type: ACTIVE_COMPARATOR): Sublingual tablets
- Placebo (Type: PLACEBO_COMPARATOR): Sublingual tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Financial Incentives for Smoking Cessation Among Disadvantaged Pregnant Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria for two intervention arms:~* report being smokers at the time that they learned of the current pregnancy;~* report smoking in the 7 days prior to the first prenatal care visit with biochemical verification;~* \< 25 weeks gestation;~* English speaking;~* plan on remaining in the geographical area through 12months postpartum.~Inclusion Criteria for never-smoker comparison condition:~* report being nonsmokers at the time they learned of the current pregnancy;~* report no smoking in the past 6 month;~* Biochemical verification of non-smoker status;~* report smoking \< 100 cigarettes in their lifetime;~Exclusion criteria:~* \> 25 weeks gestation;~* unavailable for routine assessments through 1 year postpartum;~* opioid substitution therapy;~* untreated/unstable serious mental illness

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Best practices for pregnant smokers (Type: EXPERIMENTAL): Five As plus referral to pregnancy-specific tobacco quit line
- Best practices plus financial incentives (Type: EXPERIMENTAL): Best practices plus providing financial incentives contingent on biochemically verified abstinence. Incentives are in the form of vouchers exchangeable for retail items and available through 12-weeks postpartum.
- Never-smoker comparison condition (Type: NO_INTERVENTION): We will follow a group of never-smoker pregnant women matched to smokers on key sociodemographic and obstetrical characteristics for purposes of comparisons in birth/health outcomes at delivery and through 1 year postpartum

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Confirmed diagnosis of B-cell chronic lymphocytic leukemia (CLL) based on the following criteria:~  * Peripheral blood lymphocytosis \> 5,000/mm\^3~ * Co-expression of CD5, CD19 or CD20, and CD23 surface antigens~ * Clonal kappa or lambda light chain expression~* No recurrent or refractory CLL~* No other lymphoproliferative diseases or diseases due to transformation of CLL, such as prolymphocytic leukemia or Richter's syndrome~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Karnofsky 60-100%~Life expectancy~* At least 12 weeks~Hematopoietic~* See Disease Characteristics~Hepatic~* Bilirubin \< 1.5 mg/dL~* AST \< 2.5 times upper limit of normal~Renal~* Creatinine ≤ 1.5 mg/dL~Cardiovascular~* No cardiac arrhythmia within the past 6 months~* No myocardial infarction within the past 6 months~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use at least 1 highly active and 1 additional method of contraception for 4 weeks before, during, and for at least 4 weeks after study treatment~* Patients must have sufficient mental capacity to understand the study explanation and provide informed consent~* No other malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix~* No active serious infection uncontrolled by antibiotics~* No medical condition or reason that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* No prior therapy for CLL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose escalation (Type: EXPERIMENTAL): Thalidomide (100 mg/day, 200 mg/day, or 300 mg/day) on Day 1 followed by Fludarabine 25 mg/m2/day for 5 days starting on Day 7 (cycle = 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male, non-smoker, 21 - 75 years of age inclusive.~2. Female, non-smoker, 40 - 75 years of age inclusive.~3. Post-menopausal women, as defined by lack of menses for at least 2 years and age \> 55, OR history of documented bilateral surgical oophorectomy, confirmed with an elevated follicle-stimulating hormone (FSH) at screening.~4. HDL concentration (≤ 50 mg/dl women, ≤ 40mg/dl men)~5. TG concentration 150-500 mg/dl, inclusive~6. Ability to give informed consent~Exclusion Criteria:~1. Subject has history of diabetes mellitus, active hepatitis, gall bladder disease, gastric bypass surgery, or clinically significant abnormalities on screening (prestudy) physical examination or laboratory tests.~2. Screening laboratory tests with hematocrit \<30%, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \> 2X upper limit of normal, abnormal thyroid-stimulating hormone (TSH), fasting glucose ≥126 mg/dl.~3. Renal impairment with creatinine clearance \< 80 ml/min.~4. Treatment within the last 6 months with drugs known to alter lipid metabolism including beta blockers, thiazide diuretics, bile acid resins, ezetimibe, fibrates, niacin, and fish oils (see Appendix 1). Washout of fibrates is not permitted.~5. Treatment with drugs known to interact with ABT-335, e.g., warfarin (see Appendix 1).~6. Treatment with HMG CoA reductase inhibitors (statins) within the past 4 weeks (see Appendix 1).~7. History of allergy to egg or soy products.~8. History of coronary heart disease (CHD), stroke or revascularization procedure in the six months prior to Visit 1.~9. Current or recent history (past 12 months) of drug abuse or alcohol abuse. Alcohol abuse will be defined as \>14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5 oz hard liquor).~10. Participation in another clinical trial or exposure to any investigational agent within 30 days before visit 1.~11. Individual has a condition the Principal Investigator believes would interfere with his/her ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the subject at undue risk.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Abt-335 (Type: EXPERIMENTAL): ABT-335 (choline fenofibrate)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosis of type 2 diabetes mellitus prior to informed consent~2. Male and female patients on diet and exercise regimen who are drug-naive, defined as absence of any oral antidiabetic therapy for 12 weeks prior to randomization~3. HbA1c \>=7.5% and \<= 12% (\>=58.5 mmol/mol and \<=107.7 mmol/mol)~4. Body Mass Index (BMI) \<= 45 kg/m2 at screening~Exclusion criteria:~1. Uncontrolled hyperglycemia with a glucose level \>240 mg/dl (\>13.3 mmol/L) after an overnight fast during placebo run-in and confirmed by a second laboratory measurement (not on the same day)~2. Any antidiabetic drug within 12 weeks prior to randomization~3. Impaired renal function, defined as estimated creatinine clearance rate (eCCr) \<60 ml/min (Cockcroft-Gault formula) as determined during screening and/or run-in period~4. Contraindications to metformin according to the local label

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empagliflozin low dose qd (Type: EXPERIMENTAL): Empagliflozin low dose once daily
- Empagliflozin high dose qd (Type: EXPERIMENTAL): Empagliflozin high dose once daily
- OL empa high dose + met 1000 mg bid (Type: EXPERIMENTAL): Open label empagliflozin high dose split twice daily + metformin 1000 mg twice daily - Patients are no longer enrolled into this arm because of change in the inclusion criteria in protocol version 2.0 all patients are now enrolled into remaining double-blind arms. Patients already enrolled in the open-label arm according to protocol version 1.0 can complete the study.
- Empagliflozin low dose + met 500 mg bid (Type: EXPERIMENTAL): Empagliflozin low dose split twice daily + metformin 500 mg twice daily
- Empagliflozin low dose + met 1000 mg bid (Type: EXPERIMENTAL): Empagliflozin low dose split twice daily + metformin 1000 mg twice daily
- Empagliflozin high dose + met 500 mg bid (Type: EXPERIMENTAL): Empagliflozin high dose split twice daily + metformin 500 mg twice daily
- Empagliflozin high dose + met 1000mg bid (Type: EXPERIMENTAL): Empagliflozin high dose split twice daily + metformin 1000 mg twice daily
- Metformin 500 mg bid (Type: EXPERIMENTAL): Metformin 500 mg twice daily
- Metformin 1000 mg bid (Type: EXPERIMENTAL): Metformin 1000 mg twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Single-dose Steroid Application for the Treatment of Nausea and Vomiting After Thyroid Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18~* Planned partial or total thyroidectomy~Exclusion Criteria:~* History of adverse effects to dexamethasone or propyleneglycol or di-natrium-EDTA~* Patients with chronic pain~* Necessity for opioids-application in the postoperative course~* Not possible administration of a cervical block (0.5% bupivacaine at a dose of 20ml)~* Patients with Diabetes mellitus~* Pregnancy (test in young women)~* Glaucoma~* Patients who received antiemetic therapy within 48h before surgery~* Patients with acute pain requiring painkillers others than paracetamol or more than single dose NSAR treatment within 48h before surgery~* Use of psychotropic drugs~* Incompliant patients~* Preoperatively high suspicion of malignancy~* Re-operations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexamethasone injection (Type: ACTIVE_COMPARATOR): Administration of 8mg(2ml) intravenous Dexamethasone (Mephameson®)
- Placebo (NaCl 0.9%) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Adherence to Cognitive Rehabilitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of psychotic disorder~* 18 years old or older~Exclusion Criteria:~* meeting criteria for substance abuse/dependence in past 30 days~* psychiatric hospitalization in past 30 days~* change in psychiatric medications in past 30 days~* severe auditory/visual impairment~* evidence of developmental disability

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MI condition (Type: EXPERIMENTAL): motivational interview condition
- CI condition (Type: SHAM_COMPARATOR): learning style interview condition

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Platelet Rich Plasma vs Hyaluronic-Acid in Hip OA (Osteoarthritis)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female age 30-72 inclusive.~* Symptomatic early OA of the hip (Kellgren-Lawrence Grade 1-2-3) documented by x-ray taken within the past 6 months.~* Women of childbearing potential will be allowed to enroll but must be willing to practice one highly effective method of contraception (oral, injectable or implanted hormonal methods of contraception, placement of an intrauterine device (IUD) or intrauterine system (IUS) condom or occlusive cap with spermicidal foam/gel/film/cream/suppository, male sterilization, or true abstinence) throughout the study.~Exclusion Criteria:~* Patients with polyarticular disease.~* Patients with major conditions such as poorly control diabetes, Cardiac Heart Failure (CHF), Chronic Obstructive Pulmonary Disease (COPD) or untreated depression~* Patients with known blood disorders (Blood disorders (thrombopathy, thrombocytopenia, anemia with hemoglobin \<9g/dL).~* Patients who had intra-articular treatment with steroids within 6 months of randomization in this study or received more than 3 previous intra-articular steroid injections to the effected hip.~* Patients who are pregnant or nursing at the time of consent.~* Patients with inflammatory arthritic conditions (e.g. rheumatoid arthritis)~* Non-English speaking patients. (Scores used for evaluation have not been validated in Spanish)~* Patients who had previous hip surgery~* Additional disabilities in any of the lower limbs that would interfere with any of the clinical assessments.~* Chronic use of NSAID (defined as taking NSAID regularly every week for the last 6 months), steroids or chemotherapy drugs~* Treatment with NSAIDs within 2 days prior to randomization in this study~* Patients with a BMI over 30. Due to the fact that this study utilize an injection technique which may be inaccurate in obese subjects.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- Autologous PRP Hip Injection (Type: EXPERIMENTAL): Patients randomized to this group of treatment will receive 3 blinded hip intra-articular injections of autologous Platelet-Rich Plasma one week apart from each other.
- Hyaluronic Acid Hip Injection (Type: ACTIVE_COMPARATOR): Patients randomized to this group of treatment will receive 3 blinded hip intra-articular injections of hyaluronic acid (SUPARTZ hyaluronate/2.5ml) one week apart each other.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete